{"gene":"LMO3","run_date":"2026-04-28T18:30:27","timeline":{"discoveries":[{"year":2005,"finding":"LMO3 physically associates with the neuronal bHLH transcription factor HEN2 in the mammalian cell nucleus, as demonstrated by co-immunoprecipitation and immunostaining; stable overexpression of LMO3 in SH-SY5Y neuroblastoma cells increased cell growth, promoted anchorage-independent colony formation, and accelerated tumor growth in nude mice, establishing LMO3 as an oncogene in neuroblastoma.","method":"Co-immunoprecipitation, immunostaining, stable overexpression, soft-agar colony assay, xenograft tumor model","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP plus multiple orthogonal functional assays (in vitro and in vivo) in a single study","pmids":["15930276"],"is_preprint":false},{"year":2011,"finding":"LMO3 forms a transcriptional complex with HEN2 that acts as an upstream mediator driving Mash1 expression in neuroblastoma: the LMO3/HEN2 complex physically associates with HES1 (a negative regulator of Mash1), reduces HES1 recruitment to the Mash1 promoter, and thereby de-represses Mash1 transcription. siRNA-mediated knockdown of LMO3 inhibited SH-SY5Y cell growth with concomitant down-regulation of Mash1; luciferase reporter and chromatin immunoprecipitation assays confirmed the mechanism.","method":"siRNA knockdown, luciferase reporter assay, chromatin immunoprecipitation (ChIP), co-immunoprecipitation","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (ChIP, reporter assay, Co-IP, KD phenotype) in a single study","pmids":["21573214"],"is_preprint":false},{"year":2009,"finding":"LMO3 directly interacts with the DNA-binding domain of p53 both in vitro and in vivo; LMO3 expression represses p53-dependent transcription of target genes by suppressing promoter activation while paradoxically facilitating p53 binding to its response elements, indicating LMO3 acts as a co-repressor of p53 without inhibiting its DNA binding.","method":"In vitro binding assay, co-immunoprecipitation, chromatin immunoprecipitation (ChIP), luciferase reporter assay","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro and in vivo interaction demonstrated with multiple orthogonal methods including ChIP and reporter assay","pmids":["19995558"],"is_preprint":false},{"year":2013,"finding":"In human adipogenesis, glucocorticoids (GCs) induce LMO3 expression via the glucocorticoid receptor and a positive feedback loop involving 11β-HSD1; LMO3 overexpression promoted adipogenesis while LMO3 silencing suppressed it, acting via regulation of the pro-adipogenic PPARγ axis. This mechanism was absent in murine adipogenesis, identifying LMO3 as a human-specific regulator of adipogenesis.","method":"Overexpression, siRNA knockdown, GC receptor pathway analysis, adipose stromal cell differentiation assay","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 — clean gain- and loss-of-function with defined molecular pathway (GR→LMO3→PPARγ) and orthogonal methods","pmids":["23823477"],"is_preprint":false},{"year":2013,"finding":"LMO3 is a direct transcriptional target of NKX2-1 in lung adenocarcinoma; genome-wide ChIP-seq identified NKX2-1 binding at the LMO3 locus, and NKX2-1 cooperates with FOXA1 to regulate LMO3 gene expression. RNAi depletion of LMO3 selectively reduced cell survival in NKX2-1-amplified cells but not in non-amplified cells, placing LMO3 downstream of NKX2-1 in a cancer-relevant transcriptional circuit.","method":"Genome-wide ChIP-seq (cistromic analysis), RNAi knockdown, overexpression, cell viability assay","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1-2 — genome-wide cistromic analysis combined with functional RNAi validation in multiple cell line contexts","pmids":["23322301"],"is_preprint":false},{"year":2018,"finding":"LMO3 directly interacts with the Hippo pathway kinase LATS1, suppressing LATS1-mediated phosphorylation of YAP and inhibiting Hippo signaling; this promotes HCC cell invasion and anoikis resistance. Recombinant LMO3 protein administration recapitulated activation of Rho GTPases and YAP, and Hippo pathway inhibitors abrogated LMO3-induced invasion, confirming the mechanistic link.","method":"Co-immunoprecipitation (direct interaction), knockdown, recombinant protein administration, in vivo metastasis model, pharmacological inhibition","journal":"Journal of experimental & clinical cancer research","confidence":"High","confidence_rationale":"Tier 2 — direct protein interaction demonstrated by Co-IP, validated by multiple orthogonal functional assays in vitro and in vivo","pmids":["30219064"],"is_preprint":false},{"year":2015,"finding":"miR-630 directly targets LMO3 mRNA and suppresses LMO3 expression; restoration of LMO3 reversed the tumor-suppressive effects of miR-630 on NSCLC cell proliferation, migration, and invasion, demonstrating that miR-630 acts through LMO3 to regulate lung cancer cell behavior.","method":"miRNA overexpression, luciferase reporter assay (target validation), LMO3 restoration rescue experiment, cell proliferation/invasion assays","journal":"American journal of translational research","confidence":"Medium","confidence_rationale":"Tier 2-3 — target validation with rescue experiment, single lab","pmids":["26328011"],"is_preprint":false},{"year":2015,"finding":"miR-101 indirectly suppresses LMO3 expression in glioma by reversing hypomethylation of the LMO3 promoter; mechanistically, miR-101 inhibits EZH2, DNMT3A, and EED (reducing H3K27me3) and modulates SUV39H1/2, G9a, and PHF8 (affecting H3K9me3), thereby altering histone modifications and transcription factor (USF, MZF1) occupancy at the LMO3 promoter.","method":"miRNA overexpression, MeDIP-Chip, chromatin immunoprecipitation (ChIP) for histone marks, qPCR","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2-3 — ChIP for multiple marks plus epigenetic mechanism, single lab","pmids":["25829251"],"is_preprint":false},{"year":2018,"finding":"LMO3 promotes gastric cancer cell invasion and proliferation through activation of Akt/mTOR and Akt/GSK3β signaling; LMO3 knockdown reduced phosphorylation of these pathway components, and pharmacological inhibition of mTOR (dactolisib) or GSK3β (CHIR-98014) selectively abrogated recombinant LMO3-induced phenotypes.","method":"siRNA knockdown, recombinant protein administration, pharmacological inhibition, western blotting, invasion/proliferation assays","journal":"International journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2-3 — pathway placement by pharmacological rescue of KD phenotype, single lab","pmids":["29436606"],"is_preprint":false},{"year":2004,"finding":"Combined null mutation of both Lmo1 and Lmo3 genes in mice causes perinatal lethality without gross anatomical defects, revealing functional redundancy between LMO1 and LMO3 during embryogenesis; individual Lmo3 null mice show no discernible phenotype, indicating LMO3 is dispensable when LMO1 is present.","method":"Gene targeting (knockout mice), compound Lmo1/Lmo3 double null mutation, phenotypic analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — clean genetic epistasis via double knockout in mouse, well-controlled developmental study","pmids":["14966285"],"is_preprint":false},{"year":1997,"finding":"Lmo1, Lmo2, and Lmo3 are expressed in distinct but partially overlapping cell-type-specific patterns in the adult mouse brain including hippocampus, caudate-putamen, and cortex; seizure activity differentially regulates their expression—Lmo1 mRNA increases while Lmo2 and Lmo3 mRNAs decrease in hippocampal neurons after kainic acid-induced limbic seizures, with maximal change at 6 h and return to baseline by 24 h.","method":"In situ hybridization, immunohistochemistry in transgenic reporter mice, kainic acid seizure model","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization by ISH/IHC with activity-regulated expression as functional correlate, single lab","pmids":["9204936"],"is_preprint":false}],"current_model":"LMO3 is a nuclear LIM-only scaffold protein that modulates transcription by forming protein complexes with partners including HEN2, HES1, and p53: in neuroblastoma it drives oncogenesis by assembling an LMO3/HEN2 complex that displaces the repressor HES1 from the Mash1 promoter, while also co-repressing p53 transcriptional activity without blocking its DNA binding; in lung adenocarcinoma LMO3 is a direct NKX2-1/FOXA1 transcriptional target required for cancer cell survival; in human adipocytes it is glucocorticoid-induced via GR/11β-HSD1 feedback and promotes PPARγ-dependent adipogenesis; and in hepatocellular and gastric cancers it promotes invasion and survival by interacting with LATS1 to suppress Hippo/YAP signaling and by activating Akt/mTOR/GSK3β pathways, respectively."},"narrative":{"teleology":[{"year":1997,"claim":"Establishing that LMO3 is expressed in specific neuronal populations in the adult brain and is dynamically regulated by neural activity resolved where this LIM-only gene operates in the CNS.","evidence":"In situ hybridization and immunohistochemistry in mouse brain with kainic acid seizure model","pmids":["9204936"],"confidence":"Medium","gaps":["Downstream transcriptional targets in neurons remain unidentified","Functional consequence of seizure-induced LMO3 downregulation is unknown"]},{"year":2004,"claim":"Demonstrating that Lmo3-null mice are phenotypically normal but Lmo1/Lmo3 double-null mice die perinatally established functional redundancy between LMO1 and LMO3 during development and revealed an essential collective role.","evidence":"Gene-targeted knockout mice; compound Lmo1/Lmo3 double-null phenotypic analysis","pmids":["14966285"],"confidence":"High","gaps":["Specific cell types or developmental processes requiring LMO1/LMO3 not identified","Whether LMO3 and LMO1 share the same protein partners in embryogenesis is unknown"]},{"year":2005,"claim":"Identifying LMO3 as a nuclear interactor of HEN2 that promotes neuroblastoma growth and tumorigenesis established LMO3 as an oncogene and defined its first binding partner.","evidence":"Co-immunoprecipitation, immunostaining, stable overexpression in SH-SY5Y cells, soft-agar assay, and nude-mouse xenograft","pmids":["15930276"],"confidence":"High","gaps":["Transcriptional targets downstream of the LMO3/HEN2 complex were not identified","The domain(s) of LMO3 required for HEN2 binding were not mapped"]},{"year":2009,"claim":"Showing that LMO3 directly binds the p53 DNA-binding domain and co-represses p53 target gene transcription — without blocking p53 chromatin occupancy — revealed a second transcription-factor partner and an unexpected co-repressor mechanism.","evidence":"In vitro binding, co-immunoprecipitation, ChIP, and luciferase reporter assays","pmids":["19995558"],"confidence":"High","gaps":["The co-repressor mechanism (e.g., recruited histone modifiers) is not defined","Whether p53 co-repression contributes to neuroblastoma oncogenesis in vivo is untested"]},{"year":2011,"claim":"Elucidating that the LMO3/HEN2 complex displaces the repressor HES1 from the Mash1 promoter to de-repress Mash1 transcription provided the first complete mechanistic circuit for LMO3-driven neuroblastoma gene regulation.","evidence":"ChIP, luciferase reporter, co-immunoprecipitation, and siRNA knockdown in SH-SY5Y cells","pmids":["21573214"],"confidence":"High","gaps":["Whether Mash1 is the sole or primary oncogenic effector downstream of LMO3/HEN2 is unclear","Structural basis for HES1 displacement by the LMO3/HEN2 complex is unknown"]},{"year":2013,"claim":"Identifying LMO3 as a direct NKX2-1/FOXA1 transcriptional target required for survival in NKX2-1-amplified lung adenocarcinoma, and independently as a glucocorticoid-induced human-specific driver of PPARγ-dependent adipogenesis, broadened LMO3 function beyond neuroblastoma to distinct tissue contexts.","evidence":"ChIP-seq cistromics with RNAi survival assays in lung cancer lines; GR pathway analysis with gain/loss-of-function in human adipose stromal cells","pmids":["23322301","23823477"],"confidence":"High","gaps":["Direct transcriptional targets of LMO3 in adipocytes and lung cancer cells are not defined","Protein partners mediating LMO3 action in adipogenesis are unknown","Why LMO3 adipogenic function is absent in mouse remains unexplained"]},{"year":2015,"claim":"Demonstrating that miR-630 directly targets LMO3 mRNA in NSCLC and that miR-101 indirectly suppresses LMO3 via epigenetic remodeling of its promoter in glioma established upstream regulatory layers controlling LMO3 expression in cancers.","evidence":"Luciferase 3′-UTR reporter with rescue experiments (miR-630/NSCLC); MeDIP-Chip and ChIP for histone marks (miR-101/glioma)","pmids":["26328011","25829251"],"confidence":"Medium","gaps":["Single-lab findings for each miRNA; independent replication lacking","Whether these miRNAs regulate LMO3 in non-cancer contexts is untested"]},{"year":2018,"claim":"Identifying LMO3 as a direct LATS1 interactor that suppresses Hippo/YAP signaling in HCC, and as an activator of Akt/mTOR/GSK3β signaling in gastric cancer, revealed that LMO3 scaffolding extends to cytoplasmic kinase pathways beyond classical transcriptional regulation.","evidence":"Co-immunoprecipitation of LMO3–LATS1, recombinant protein rescue, pharmacological inhibitors of mTOR and GSK3β in functional assays, in vivo metastasis model","pmids":["30219064","29436606"],"confidence":"High","gaps":["How a nuclear LIM-only protein accesses cytoplasmic LATS1 is mechanistically unexplained","Direct versus indirect activation of Akt by LMO3 is not resolved","Gastric cancer pathway findings are from a single lab without independent confirmation"]},{"year":null,"claim":"Key unresolved questions include the structural basis for LMO3 partner selectivity across tissues, the identity of direct transcriptional targets beyond Mash1, and whether the cytoplasmic kinase interactions (LATS1, Akt) require shuttling or are mediated by distinct LMO3 pools.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal or cryo-EM structure of LMO3 in complex with any partner","Genome-wide direct target identification (e.g., CUT&RUN for LMO3-containing complexes) has not been performed","Nuclear–cytoplasmic distribution and shuttling of LMO3 have not been systematically characterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[1,2,5]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,2,3]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,1,2]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,8]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,1,4,5]}],"complexes":["LMO3/HEN2 transcriptional complex"],"partners":["HEN2","HES1","TP53","LATS1","NKX2-1","FOXA1"],"other_free_text":[]},"mechanistic_narrative":"LMO3 is a nuclear LIM-only transcriptional scaffold that lacks intrinsic DNA-binding activity and instead modulates gene expression by assembling protein–protein complexes with diverse transcription factors and signaling kinases. In neuroblastoma, LMO3 forms a complex with the bHLH factor HEN2 that sequesters the repressor HES1 away from the Mash1 promoter, de-repressing Mash1 transcription and promoting tumor growth [PMID:15930276, PMID:21573214]; LMO3 also directly binds the p53 DNA-binding domain and co-represses p53-dependent transcription without blocking p53 chromatin occupancy [PMID:19995558]. Beyond neural cancers, LMO3 functions as a human-specific glucocorticoid-induced regulator of PPARγ-dependent adipogenesis [PMID:23823477], and in hepatocellular carcinoma it suppresses Hippo signaling by interacting with the kinase LATS1 to block YAP phosphorylation, thereby driving invasion and anoikis resistance [PMID:30219064]. Lmo3-null mice are viable due to functional redundancy with Lmo1, but compound Lmo1/Lmo3 double-null mice die perinatally, establishing an essential shared developmental role [PMID:14966285]."},"prefetch_data":{"uniprot":{"accession":"Q8TAP4","full_name":"LIM domain only protein 3","aliases":["Neuronal-specific transcription factor DAT1","Rhombotin-3"],"length_aa":145,"mass_kda":16.6,"function":"","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/Q8TAP4/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/LMO3","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/LMO3","total_profiled":1310},"omim":[{"mim_id":"616792","title":"NEUROBLASTOMA, SUSCEPTIBILITY TO, 7; NBLST7","url":"https://www.omim.org/entry/616792"},{"mim_id":"180386","title":"LIM DOMAIN ONLY 3; LMO3","url":"https://www.omim.org/entry/180386"},{"mim_id":"180385","title":"LIM DOMAIN ONLY 2; LMO2","url":"https://www.omim.org/entry/180385"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":110.4},{"tissue":"intestine","ntpm":67.4}],"url":"https://www.proteinatlas.org/search/LMO3"},"hgnc":{"alias_symbol":["Rhom-3","DAT1"],"prev_symbol":["RBTNL2"]},"alphafold":{"accession":"Q8TAP4","domains":[{"cath_id":"2.10.110.10","chopping":"1-72","consensus_level":"medium","plddt":87.8935,"start":1,"end":72},{"cath_id":"2.10.110.10","chopping":"74-137","consensus_level":"medium","plddt":93.4975,"start":74,"end":137}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TAP4","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TAP4-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TAP4-F1-predicted_aligned_error_v6.png","plddt_mean":88.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=LMO3","jax_strain_url":"https://www.jax.org/strain/search?query=LMO3"},"sequence":{"accession":"Q8TAP4","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8TAP4.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8TAP4/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TAP4"}},"corpus_meta":[{"pmid":"16894395","id":"PMC_16894395","title":"The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes.","date":"2006","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/16894395","citation_count":417,"is_preprint":false},{"pmid":"10208453","id":"PMC_10208453","title":"Mapping susceptibility loci in attention deficit hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children.","date":"1999","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/10208453","citation_count":285,"is_preprint":false},{"pmid":"16309561","id":"PMC_16309561","title":"The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density.","date":"2005","source":"BMC genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16309561","citation_count":239,"is_preprint":false},{"pmid":"16168728","id":"PMC_16168728","title":"Dissecting the attention deficit hyperactivity disorder (ADHD) phenotype: sustained attention, response variability and spatial attentional asymmetries in relation to dopamine transporter (DAT1) genotype.","date":"2005","source":"Neuropsychologia","url":"https://pubmed.ncbi.nlm.nih.gov/16168728","citation_count":178,"is_preprint":false},{"pmid":"10596245","id":"PMC_10596245","title":"Association of the dopamine transporter gene (DAT1) with poor methylphenidate response.","date":"1999","source":"Journal of the American Academy of Child and Adolescent Psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/10596245","citation_count":173,"is_preprint":false},{"pmid":"15809660","id":"PMC_15809660","title":"Association of the dopamine transporter (DAT1) 10/10-repeat genotype with ADHD symptoms and response inhibition in a general population sample.","date":"2005","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/15809660","citation_count":161,"is_preprint":false},{"pmid":"15724142","id":"PMC_15724142","title":"Differential effects of DRD4 and DAT1 genotype on fronto-striatal gray matter volumes in a sample of subjects with attention deficit hyperactivity disorder, their unaffected siblings, and controls.","date":"2005","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/15724142","citation_count":160,"is_preprint":false},{"pmid":"19890261","id":"PMC_19890261","title":"Multicenter analysis of the SLC6A3/DAT1 VNTR haplotype in persistent ADHD suggests differential involvement of the gene in childhood and persistent ADHD.","date":"2009","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19890261","citation_count":147,"is_preprint":false},{"pmid":"12874502","id":"PMC_12874502","title":"Functional effects of the DAT1 polymorphism on EEG measures in ADHD.","date":"2003","source":"Journal of the American Academy of Child and Adolescent Psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/12874502","citation_count":128,"is_preprint":false},{"pmid":"15856082","id":"PMC_15856082","title":"Novelty seeking and stereotypic activation of behavior in mice with disruption of the Dat1 gene.","date":"2005","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15856082","citation_count":120,"is_preprint":false},{"pmid":"12898575","id":"PMC_12898575","title":"Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD.","date":"2003","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12898575","citation_count":111,"is_preprint":false},{"pmid":"15930276","id":"PMC_15930276","title":"LMO3 interacts with neuronal transcription factor, HEN2, and acts as an oncogene in neuroblastoma.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15930276","citation_count":100,"is_preprint":false},{"pmid":"10889530","id":"PMC_10889530","title":"Systematic screening for DNA sequence variation in the coding region of the human dopamine transporter gene (DAT1).","date":"2000","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/10889530","citation_count":98,"is_preprint":false},{"pmid":"9152988","id":"PMC_9152988","title":"Association of polymorphisms of dopamine D2 receptor (DRD2), and dopamine transporter (DAT1) genes with schizoid/avoidant behaviors (SAB).","date":"1997","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/9152988","citation_count":92,"is_preprint":false},{"pmid":"9670597","id":"PMC_9670597","title":"The relation of the dopamine transporter gene (DAT1) to symptoms of internalizing disorders in children.","date":"1998","source":"Behavior genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9670597","citation_count":90,"is_preprint":false},{"pmid":"12660802","id":"PMC_12660802","title":"Linkage disequilibrium mapping at DAT1, DRD5 and DBH narrows the search for ADHD susceptibility alleles at these loci.","date":"2003","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/12660802","citation_count":89,"is_preprint":false},{"pmid":"25071464","id":"PMC_25071464","title":"Combinatorial expression of Lef1, Lhx2, Lhx5, Lhx9, Lmo3, Lmo4, and Prox1 helps to identify comparable subdivisions in the developing hippocampal formation of mouse and chicken.","date":"2014","source":"Frontiers in neuroanatomy","url":"https://pubmed.ncbi.nlm.nih.gov/25071464","citation_count":89,"is_preprint":false},{"pmid":"16123773","id":"PMC_16123773","title":"Association between dopamine transporter (DAT1) genotype, left-sided inattention, and an enhanced response to methylphenidate in attention-deficit hyperactivity disorder.","date":"2005","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16123773","citation_count":80,"is_preprint":false},{"pmid":"16751296","id":"PMC_16751296","title":"DRD4 and DAT1 polymorphisms modulate human gamma band responses.","date":"2006","source":"Cerebral cortex (New York, N.Y. : 1991)","url":"https://pubmed.ncbi.nlm.nih.gov/16751296","citation_count":79,"is_preprint":false},{"pmid":"15683546","id":"PMC_15683546","title":"Transient expression analysis of allelic variants of a VNTR in the dopamine transporter gene (DAT1).","date":"2005","source":"BMC genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15683546","citation_count":79,"is_preprint":false},{"pmid":"19120712","id":"PMC_19120712","title":"Association of ADHD, tics, and anxiety with dopamine transporter (DAT1) genotype in autism spectrum disorder.","date":"2008","source":"Journal of child psychology and psychiatry, and allied disciplines","url":"https://pubmed.ncbi.nlm.nih.gov/19120712","citation_count":76,"is_preprint":false},{"pmid":"14966285","id":"PMC_14966285","title":"Null mutation of the Lmo4 gene or a combined null mutation of the Lmo1/Lmo3 genes causes perinatal lethality, and Lmo4 controls neural tube development in mice.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/14966285","citation_count":75,"is_preprint":false},{"pmid":"23032071","id":"PMC_23032071","title":"Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.","date":"2012","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23032071","citation_count":73,"is_preprint":false},{"pmid":"10578237","id":"PMC_10578237","title":"Identification of a novel polymorphism of the human dopamine transporter (DAT1) gene and the significant association with alcoholism.","date":"1999","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/10578237","citation_count":71,"is_preprint":false},{"pmid":"16702979","id":"PMC_16702979","title":"A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment.","date":"2006","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/16702979","citation_count":69,"is_preprint":false},{"pmid":"18802924","id":"PMC_18802924","title":"Association of the dopamine transporter (SLC6A3/DAT1) gene 9-6 haplotype with adult ADHD.","date":"2008","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18802924","citation_count":69,"is_preprint":false},{"pmid":"15578613","id":"PMC_15578613","title":"Quantitative trait locus analysis of candidate gene alleles associated with attention deficit hyperactivity disorder (ADHD) in five genes: DRD4, DAT1, DRD5, SNAP-25, and 5HT1B.","date":"2005","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15578613","citation_count":66,"is_preprint":false},{"pmid":"7557351","id":"PMC_7557351","title":"Population genetic study of the human dopamine transporter gene (DAT1).","date":"1995","source":"Genetic epidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/7557351","citation_count":62,"is_preprint":false},{"pmid":"17955457","id":"PMC_17955457","title":"Response to methylphenidate in adults with ADHD is associated with a polymorphism in SLC6A3 (DAT1).","date":"2008","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17955457","citation_count":61,"is_preprint":false},{"pmid":"23823477","id":"PMC_23823477","title":"Human but not mouse adipogenesis is critically dependent on LMO3.","date":"2013","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23823477","citation_count":59,"is_preprint":false},{"pmid":"16082688","id":"PMC_16082688","title":"No support for association between the dopamine transporter (DAT1) gene and ADHD.","date":"2005","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16082688","citation_count":59,"is_preprint":false},{"pmid":"23968837","id":"PMC_23968837","title":"Resting-state striato-frontal functional connectivity is sensitive to DAT1 genotype and predicts executive function.","date":"2013","source":"Cerebral cortex (New York, N.Y. : 1991)","url":"https://pubmed.ncbi.nlm.nih.gov/23968837","citation_count":59,"is_preprint":false},{"pmid":"8950413","id":"PMC_8950413","title":"Association study of bipolar disorder with candidate genes involved in catecholamine neurotransmission: DRD2, DRD3, DAT1, and TH genes.","date":"1996","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8950413","citation_count":58,"is_preprint":false},{"pmid":"18729135","id":"PMC_18729135","title":"A review and analysis of the relationship between neuropsychological measures and DAT1 in ADHD.","date":"2008","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18729135","citation_count":56,"is_preprint":false},{"pmid":"19664686","id":"PMC_19664686","title":"Potential association of DRD2 and DAT1 genetic variation with heroin dependence.","date":"2009","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/19664686","citation_count":56,"is_preprint":false},{"pmid":"23322301","id":"PMC_23322301","title":"Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target.","date":"2013","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/23322301","citation_count":54,"is_preprint":false},{"pmid":"14755448","id":"PMC_14755448","title":"Clinical features of psychotic disorders and polymorphisms in HT2A, DRD2, DRD4, SLC6A3 (DAT1), and BDNF: a family based association study.","date":"2004","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14755448","citation_count":52,"is_preprint":false},{"pmid":"16342279","id":"PMC_16342279","title":"Genotypic interaction between DRD4 and DAT1 loci is a high risk factor for attention-deficit/hyperactivity disorder in Chilean families.","date":"2006","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16342279","citation_count":50,"is_preprint":false},{"pmid":"15211638","id":"PMC_15211638","title":"Family-based and case-control association studies of DRD4 and DAT1 polymorphisms in Chinese attention deficit hyperactivity disorder patients suggest long repeats contribute to genetic risk for the disorder.","date":"2004","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15211638","citation_count":48,"is_preprint":false},{"pmid":"20141587","id":"PMC_20141587","title":"The dopamine transporter gene (DAT1) polymorphism is associated with premature ejaculation.","date":"2010","source":"The journal of sexual medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20141587","citation_count":48,"is_preprint":false},{"pmid":"17314918","id":"PMC_17314918","title":"Dopamine transporter gene (DAT1) associated with appetite suppression to methylphenidate in a case-control study of binge eating disorder.","date":"2007","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17314918","citation_count":46,"is_preprint":false},{"pmid":"9204936","id":"PMC_9204936","title":"Expression of LIM protein genes Lmo1, Lmo2, and Lmo3 in adult mouse hippocampus and other forebrain regions: differential regulation by seizure activity.","date":"1997","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/9204936","citation_count":45,"is_preprint":false},{"pmid":"21596533","id":"PMC_21596533","title":"Relationship of DAT1 and adult ADHD to task-positive and task-negative working memory networks.","date":"2011","source":"Psychiatry research","url":"https://pubmed.ncbi.nlm.nih.gov/21596533","citation_count":44,"is_preprint":false},{"pmid":"11104840","id":"PMC_11104840","title":"DRD3 and DAT1 genes in schizophrenia: an association study.","date":"2000","source":"Journal of psychiatric research","url":"https://pubmed.ncbi.nlm.nih.gov/11104840","citation_count":43,"is_preprint":false},{"pmid":"9433566","id":"PMC_9433566","title":"Linkage disequilibrium between the dopamine transporter gene (DAT1) and bipolar disorder: extending the transmission disequilibrium test (TDT) to examine genetic heterogeneity.","date":"1997","source":"Genetic epidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/9433566","citation_count":43,"is_preprint":false},{"pmid":"20141527","id":"PMC_20141527","title":"The role of the dopamine transporter DAT1 genotype on the neural correlates of cognitive flexibility.","date":"2010","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/20141527","citation_count":43,"is_preprint":false},{"pmid":"16569110","id":"PMC_16569110","title":"An association between the DAT1 polymorphism and smoking behavior in young adults from the National Longitudinal Study of Adolescent Health.","date":"2006","source":"Health psychology : official journal of the Division of Health Psychology, American Psychological Association","url":"https://pubmed.ncbi.nlm.nih.gov/16569110","citation_count":43,"is_preprint":false},{"pmid":"19450132","id":"PMC_19450132","title":"Polymorphisms in the dopamine transporter gene (SLC6A3/DAT1) and alcohol dependence in humans: a systematic review.","date":"2009","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/19450132","citation_count":42,"is_preprint":false},{"pmid":"21207241","id":"PMC_21207241","title":"A family based association study of DRD4, DAT1, and 5HTT and continuous traits of attention-deficit hyperactivity disorder.","date":"2011","source":"Behavior genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21207241","citation_count":42,"is_preprint":false},{"pmid":"26328011","id":"PMC_26328011","title":"miR-630 targets LMO3 to regulate cell growth and metastasis in lung cancer.","date":"2015","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/26328011","citation_count":40,"is_preprint":false},{"pmid":"21573214","id":"PMC_21573214","title":"Oncogenic LMO3 collaborates with HEN2 to enhance neuroblastoma cell growth through transactivation of Mash1.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21573214","citation_count":38,"is_preprint":false},{"pmid":"19995558","id":"PMC_19995558","title":"LMO3 interacts with p53 and inhibits its transcriptional activity.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19995558","citation_count":38,"is_preprint":false},{"pmid":"16356184","id":"PMC_16356184","title":"Sequence analysis of Drd2, Drd4, and Dat1 in SHR and WKY rat strains.","date":"2005","source":"Behavioral and brain functions : BBF","url":"https://pubmed.ncbi.nlm.nih.gov/16356184","citation_count":38,"is_preprint":false},{"pmid":"27676100","id":"PMC_27676100","title":"DAT1 methylation is associated with methylphenidate response on oppositional and hyperactive-impulsive symptoms in children and adolescents with ADHD.","date":"2016","source":"The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/27676100","citation_count":38,"is_preprint":false},{"pmid":"16917950","id":"PMC_16917950","title":"Absence of association with DAT1 polymorphism and response to methylphenidate in a sample of adults with ADHD.","date":"2006","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16917950","citation_count":38,"is_preprint":false},{"pmid":"21272388","id":"PMC_21272388","title":"Effects of two dopamine-modulating genes (DAT1 9/10 and COMT Val/Met) on n-back working memory performance in healthy volunteers.","date":"2011","source":"Psychological medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21272388","citation_count":36,"is_preprint":false},{"pmid":"24521003","id":"PMC_24521003","title":"Genetics of preparation and response control in ADHD: the role of DRD4 and DAT1.","date":"2014","source":"Journal of child psychology and psychiatry, and allied disciplines","url":"https://pubmed.ncbi.nlm.nih.gov/24521003","citation_count":35,"is_preprint":false},{"pmid":"18070248","id":"PMC_18070248","title":"The 3' part of the dopamine transporter gene DAT1/SLC6A3 is associated with withdrawal seizures in patients with alcohol dependence.","date":"2007","source":"Alcoholism, clinical and experimental research","url":"https://pubmed.ncbi.nlm.nih.gov/18070248","citation_count":35,"is_preprint":false},{"pmid":"25829251","id":"PMC_25829251","title":"MiR-101 reverses the hypomethylation of the LMO3 promoter in glioma cells.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25829251","citation_count":33,"is_preprint":false},{"pmid":"30219064","id":"PMC_30219064","title":"LMO3 promotes hepatocellular carcinoma invasion, metastasis and anoikis inhibition by directly interacting with LATS1 and suppressing Hippo signaling.","date":"2018","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/30219064","citation_count":33,"is_preprint":false},{"pmid":"24421289","id":"PMC_24421289","title":"Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol.","date":"2014","source":"Alcohol and alcoholism (Oxford, Oxfordshire)","url":"https://pubmed.ncbi.nlm.nih.gov/24421289","citation_count":33,"is_preprint":false},{"pmid":"26058807","id":"PMC_26058807","title":"A 40-bp VNTR polymorphism in the 3'-untranslated region of DAT1/SLC6A3 is associated with ADHD but not with alcoholism.","date":"2015","source":"Behavioral and brain functions : BBF","url":"https://pubmed.ncbi.nlm.nih.gov/26058807","citation_count":33,"is_preprint":false},{"pmid":"16861140","id":"PMC_16861140","title":"Striatal dopamine transporter availability and DAT-1 gene in adults with ADHD: no higher DAT availability in patients with homozygosity for the 10-repeat allele.","date":"2006","source":"The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/16861140","citation_count":33,"is_preprint":false},{"pmid":"11942948","id":"PMC_11942948","title":"Dopamine transporter gene (DAT1) VNTR polymorphism in major psychiatric disorders: family-based association study in the Bulgarian population.","date":"2002","source":"Acta psychiatrica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/11942948","citation_count":33,"is_preprint":false},{"pmid":"15274029","id":"PMC_15274029","title":"Association of the dopamine transporter gene (DAT1) core promoter polymorphism -67T variant with schizophrenia.","date":"2004","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15274029","citation_count":32,"is_preprint":false},{"pmid":"16178931","id":"PMC_16178931","title":"High sibling correlation on methylphenidate response but no association with DAT1-10R homozygosity in Dutch sibpairs with ADHD.","date":"2005","source":"Journal of child psychology and psychiatry, and allied disciplines","url":"https://pubmed.ncbi.nlm.nih.gov/16178931","citation_count":32,"is_preprint":false},{"pmid":"26206710","id":"PMC_26206710","title":"Cortical thickness differences in the prefrontal cortex in children and adolescents with ADHD in relation to dopamine transporter (DAT1) genotype.","date":"2015","source":"Psychiatry research","url":"https://pubmed.ncbi.nlm.nih.gov/26206710","citation_count":31,"is_preprint":false},{"pmid":"18553640","id":"PMC_18553640","title":"Genetic heterogeneity in ADHD: DAT1 gene only affects probands without CD.","date":"2008","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18553640","citation_count":30,"is_preprint":false},{"pmid":"24625311","id":"PMC_24625311","title":"Genetic polymorphisms of DAT1 and COMT differentially associate with actigraphy-derived sleep-wake cycles in young adults.","date":"2014","source":"Chronobiology international","url":"https://pubmed.ncbi.nlm.nih.gov/24625311","citation_count":29,"is_preprint":false},{"pmid":"20661460","id":"PMC_20661460","title":"Dopaminergic Control of Attentional Flexibility: Inhibition of Return is Associated with the Dopamine Transporter Gene (DAT1).","date":"2010","source":"Frontiers in human neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/20661460","citation_count":28,"is_preprint":false},{"pmid":"19146920","id":"PMC_19146920","title":"Genetic interaction analysis for DRD4 and DAT1 genes in a group of Mexican ADHD patients.","date":"2009","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/19146920","citation_count":27,"is_preprint":false},{"pmid":"16165273","id":"PMC_16165273","title":"Family-based association study of DAT1 and DRD4 polymorphism in Korean children with ADHD.","date":"2005","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/16165273","citation_count":27,"is_preprint":false},{"pmid":"20505554","id":"PMC_20505554","title":"Association study between the DAT1, DBH and DRD2 genes and cocaine dependence in a Spanish sample.","date":"2010","source":"Psychiatric genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20505554","citation_count":27,"is_preprint":false},{"pmid":"24487615","id":"PMC_24487615","title":"Further evidence for the association between a polymorphism in the promoter region of SLC6A3/DAT1 and ADHD: findings from a sample of adults.","date":"2014","source":"European archives of psychiatry and clinical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/24487615","citation_count":27,"is_preprint":false},{"pmid":"15768394","id":"PMC_15768394","title":"Association analysis of the dopamine transporter (DAT1)-67A/T polymorphism in bipolar disorder.","date":"2005","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15768394","citation_count":27,"is_preprint":false},{"pmid":"23224504","id":"PMC_23224504","title":"Atrazine biodegradation by Arthrobacter strain DAT1: effect of glucose supplementation and change of the soil microbial community.","date":"2012","source":"Environmental science and pollution research international","url":"https://pubmed.ncbi.nlm.nih.gov/23224504","citation_count":27,"is_preprint":false},{"pmid":"25237117","id":"PMC_25237117","title":"Dopamine DRD2/ANKK1 Taq1A and DAT1 VNTR polymorphisms are associated with a cognitive flexibility profile in pathological gamblers.","date":"2014","source":"Journal of psychopharmacology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25237117","citation_count":25,"is_preprint":false},{"pmid":"15951833","id":"PMC_15951833","title":"4-Amino-5-benzoyl-2-(4-methoxyphenylamino)thiazole (DAT1): a cytotoxic agent towards cancer cells and a probe for tubulin-microtubule system.","date":"2005","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15951833","citation_count":25,"is_preprint":false},{"pmid":"20450954","id":"PMC_20450954","title":"Variants of the SLC6A3 (DAT1) polymorphism affect performance monitoring-related cortical evoked potentials that are associated with ADHD.","date":"2010","source":"Biological psychology","url":"https://pubmed.ncbi.nlm.nih.gov/20450954","citation_count":25,"is_preprint":false},{"pmid":"16526026","id":"PMC_16526026","title":"Association of the DAT1 polymorphism with attention deficit hyperactivity disorder (ADHD): a family-based approach.","date":"2006","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16526026","citation_count":24,"is_preprint":false},{"pmid":"18553389","id":"PMC_18553389","title":"Dopamine transporter polymorphism modulates oculomotor function and DAT1 mRNA expression in schizophrenia.","date":"2009","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18553389","citation_count":23,"is_preprint":false},{"pmid":"19352220","id":"PMC_19352220","title":"Association between harmful alcohol consumption behavior and dopamine transporter (DAT1) gene polymorphisms in a male Finnish population.","date":"2009","source":"Psychiatric genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19352220","citation_count":22,"is_preprint":false},{"pmid":"22691013","id":"PMC_22691013","title":"Dopamine transporter (DAT1) VNTR polymorphism and alcoholism in two culturally different populations of south India.","date":"2012","source":"The American journal on addictions","url":"https://pubmed.ncbi.nlm.nih.gov/22691013","citation_count":22,"is_preprint":false},{"pmid":"24008096","id":"PMC_24008096","title":"Association between the DAT1 gene and spatial working memory in attention deficit hyperactivity disorder.","date":"2013","source":"The international journal of neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24008096","citation_count":21,"is_preprint":false},{"pmid":"20049490","id":"PMC_20049490","title":"Response to methylphenidate is not influenced by DAT1 polymorphisms in a sample of Brazilian adult patients with ADHD.","date":"2010","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/20049490","citation_count":21,"is_preprint":false},{"pmid":"19025233","id":"PMC_19025233","title":"Relations between multi-informant assessments of ADHD symptoms, DAT1, and DRD4.","date":"2008","source":"Journal of abnormal psychology","url":"https://pubmed.ncbi.nlm.nih.gov/19025233","citation_count":21,"is_preprint":false},{"pmid":"21592505","id":"PMC_21592505","title":"A dopamine receptor (DRD2) but not dopamine transporter (DAT1) gene polymorphism is associated with neurocognitive development of Mexican preschool children with lead exposure.","date":"2011","source":"The Journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/21592505","citation_count":20,"is_preprint":false},{"pmid":"26935821","id":"PMC_26935821","title":"Enlarged striatal volume in adults with ADHD carrying the 9-6 haplotype of the dopamine transporter gene DAT1.","date":"2016","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/26935821","citation_count":20,"is_preprint":false},{"pmid":"20170711","id":"PMC_20170711","title":"Association analysis between polymorphisms in the dopamine D2 receptor (DRD2) and dopamine transporter (DAT1) genes with cocaine dependence.","date":"2010","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/20170711","citation_count":19,"is_preprint":false},{"pmid":"29436606","id":"PMC_29436606","title":"LMO3 promotes gastric cancer cell invasion and proliferation through Akt-mTOR and Akt-GSK3β signaling.","date":"2018","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29436606","citation_count":18,"is_preprint":false},{"pmid":"23034259","id":"PMC_23034259","title":"Association analysis of dopaminergic gene variants (Comt, Drd4 And Dat1) with Alzheimer s disease.","date":"2012","source":"Journal of biological regulators and homeostatic agents","url":"https://pubmed.ncbi.nlm.nih.gov/23034259","citation_count":18,"is_preprint":false},{"pmid":"23226043","id":"PMC_23226043","title":"DRD4 and DAT1 in ADHD: Functional neurobiology to pharmacogenetics.","date":"2010","source":"Pharmacogenomics and personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23226043","citation_count":18,"is_preprint":false},{"pmid":"22646917","id":"PMC_22646917","title":"Interaction of dopamine transporter (DAT1) genotype and maltreatment for ADHD: a latent class analysis.","date":"2012","source":"Journal of child psychology and psychiatry, and allied disciplines","url":"https://pubmed.ncbi.nlm.nih.gov/22646917","citation_count":18,"is_preprint":false},{"pmid":"18331164","id":"PMC_18331164","title":"Visual search performance in children rated as good or poor attenders: the differential impact of DAT1 genotype, IQ, and chronological age.","date":"2008","source":"Neuropsychology","url":"https://pubmed.ncbi.nlm.nih.gov/18331164","citation_count":18,"is_preprint":false},{"pmid":"27327562","id":"PMC_27327562","title":"COMT and DAT1 genes are associated with hyperactivity and inattention traits in the 1993 Pelotas Birth Cohort: evidence of sex-specific combined effect.","date":"2016","source":"Journal of psychiatry & neuroscience : JPN","url":"https://pubmed.ncbi.nlm.nih.gov/27327562","citation_count":17,"is_preprint":false},{"pmid":"7590757","id":"PMC_7590757","title":"Amplification of DAT1 (human dopamine transporter gene) 3' variable region in the Japanese population.","date":"1995","source":"Human heredity","url":"https://pubmed.ncbi.nlm.nih.gov/7590757","citation_count":17,"is_preprint":false},{"pmid":"22162768","id":"PMC_22162768","title":"Dopamine transporter (DAT1) and dopamine receptor D4 (DRD4) genotypes differentially impact on electrophysiological correlates of error processing.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22162768","citation_count":17,"is_preprint":false},{"pmid":"30248905","id":"PMC_30248905","title":"Associations Between the Dopamine D4 Receptor and DAT1 Dopamine Transporter Genes Polymorphisms and Personality Traits in Addicted Patients.","date":"2018","source":"International journal of environmental research and public health","url":"https://pubmed.ncbi.nlm.nih.gov/30248905","citation_count":17,"is_preprint":false},{"pmid":"27873141","id":"PMC_27873141","title":"The Contribution of Maternal ADHD Symptomatology, Maternal DAT1, and Home Atmosphere to Child ADHD Symptomatology at 7 Years of Age.","date":"2017","source":"Journal of abnormal child psychology","url":"https://pubmed.ncbi.nlm.nih.gov/27873141","citation_count":16,"is_preprint":false},{"pmid":"25847847","id":"PMC_25847847","title":"Causal discovery in an adult ADHD data set suggests indirect link between DAT1 genetic variants and striatal brain activation during reward processing.","date":"2015","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25847847","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47790,"output_tokens":2988,"usd":0.094095},"stage2":{"model":"claude-opus-4-6","input_tokens":6358,"output_tokens":2581,"usd":0.144473},"total_usd":0.238568,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"LMO3 physically associates with the neuronal bHLH transcription factor HEN2 in the mammalian cell nucleus, as demonstrated by co-immunoprecipitation and immunostaining; stable overexpression of LMO3 in SH-SY5Y neuroblastoma cells increased cell growth, promoted anchorage-independent colony formation, and accelerated tumor growth in nude mice, establishing LMO3 as an oncogene in neuroblastoma.\",\n      \"method\": \"Co-immunoprecipitation, immunostaining, stable overexpression, soft-agar colony assay, xenograft tumor model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP plus multiple orthogonal functional assays (in vitro and in vivo) in a single study\",\n      \"pmids\": [\"15930276\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"LMO3 forms a transcriptional complex with HEN2 that acts as an upstream mediator driving Mash1 expression in neuroblastoma: the LMO3/HEN2 complex physically associates with HES1 (a negative regulator of Mash1), reduces HES1 recruitment to the Mash1 promoter, and thereby de-represses Mash1 transcription. siRNA-mediated knockdown of LMO3 inhibited SH-SY5Y cell growth with concomitant down-regulation of Mash1; luciferase reporter and chromatin immunoprecipitation assays confirmed the mechanism.\",\n      \"method\": \"siRNA knockdown, luciferase reporter assay, chromatin immunoprecipitation (ChIP), co-immunoprecipitation\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (ChIP, reporter assay, Co-IP, KD phenotype) in a single study\",\n      \"pmids\": [\"21573214\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"LMO3 directly interacts with the DNA-binding domain of p53 both in vitro and in vivo; LMO3 expression represses p53-dependent transcription of target genes by suppressing promoter activation while paradoxically facilitating p53 binding to its response elements, indicating LMO3 acts as a co-repressor of p53 without inhibiting its DNA binding.\",\n      \"method\": \"In vitro binding assay, co-immunoprecipitation, chromatin immunoprecipitation (ChIP), luciferase reporter assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro and in vivo interaction demonstrated with multiple orthogonal methods including ChIP and reporter assay\",\n      \"pmids\": [\"19995558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In human adipogenesis, glucocorticoids (GCs) induce LMO3 expression via the glucocorticoid receptor and a positive feedback loop involving 11β-HSD1; LMO3 overexpression promoted adipogenesis while LMO3 silencing suppressed it, acting via regulation of the pro-adipogenic PPARγ axis. This mechanism was absent in murine adipogenesis, identifying LMO3 as a human-specific regulator of adipogenesis.\",\n      \"method\": \"Overexpression, siRNA knockdown, GC receptor pathway analysis, adipose stromal cell differentiation assay\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean gain- and loss-of-function with defined molecular pathway (GR→LMO3→PPARγ) and orthogonal methods\",\n      \"pmids\": [\"23823477\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"LMO3 is a direct transcriptional target of NKX2-1 in lung adenocarcinoma; genome-wide ChIP-seq identified NKX2-1 binding at the LMO3 locus, and NKX2-1 cooperates with FOXA1 to regulate LMO3 gene expression. RNAi depletion of LMO3 selectively reduced cell survival in NKX2-1-amplified cells but not in non-amplified cells, placing LMO3 downstream of NKX2-1 in a cancer-relevant transcriptional circuit.\",\n      \"method\": \"Genome-wide ChIP-seq (cistromic analysis), RNAi knockdown, overexpression, cell viability assay\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genome-wide cistromic analysis combined with functional RNAi validation in multiple cell line contexts\",\n      \"pmids\": [\"23322301\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LMO3 directly interacts with the Hippo pathway kinase LATS1, suppressing LATS1-mediated phosphorylation of YAP and inhibiting Hippo signaling; this promotes HCC cell invasion and anoikis resistance. Recombinant LMO3 protein administration recapitulated activation of Rho GTPases and YAP, and Hippo pathway inhibitors abrogated LMO3-induced invasion, confirming the mechanistic link.\",\n      \"method\": \"Co-immunoprecipitation (direct interaction), knockdown, recombinant protein administration, in vivo metastasis model, pharmacological inhibition\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct protein interaction demonstrated by Co-IP, validated by multiple orthogonal functional assays in vitro and in vivo\",\n      \"pmids\": [\"30219064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"miR-630 directly targets LMO3 mRNA and suppresses LMO3 expression; restoration of LMO3 reversed the tumor-suppressive effects of miR-630 on NSCLC cell proliferation, migration, and invasion, demonstrating that miR-630 acts through LMO3 to regulate lung cancer cell behavior.\",\n      \"method\": \"miRNA overexpression, luciferase reporter assay (target validation), LMO3 restoration rescue experiment, cell proliferation/invasion assays\",\n      \"journal\": \"American journal of translational research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — target validation with rescue experiment, single lab\",\n      \"pmids\": [\"26328011\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"miR-101 indirectly suppresses LMO3 expression in glioma by reversing hypomethylation of the LMO3 promoter; mechanistically, miR-101 inhibits EZH2, DNMT3A, and EED (reducing H3K27me3) and modulates SUV39H1/2, G9a, and PHF8 (affecting H3K9me3), thereby altering histone modifications and transcription factor (USF, MZF1) occupancy at the LMO3 promoter.\",\n      \"method\": \"miRNA overexpression, MeDIP-Chip, chromatin immunoprecipitation (ChIP) for histone marks, qPCR\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — ChIP for multiple marks plus epigenetic mechanism, single lab\",\n      \"pmids\": [\"25829251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LMO3 promotes gastric cancer cell invasion and proliferation through activation of Akt/mTOR and Akt/GSK3β signaling; LMO3 knockdown reduced phosphorylation of these pathway components, and pharmacological inhibition of mTOR (dactolisib) or GSK3β (CHIR-98014) selectively abrogated recombinant LMO3-induced phenotypes.\",\n      \"method\": \"siRNA knockdown, recombinant protein administration, pharmacological inhibition, western blotting, invasion/proliferation assays\",\n      \"journal\": \"International journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — pathway placement by pharmacological rescue of KD phenotype, single lab\",\n      \"pmids\": [\"29436606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Combined null mutation of both Lmo1 and Lmo3 genes in mice causes perinatal lethality without gross anatomical defects, revealing functional redundancy between LMO1 and LMO3 during embryogenesis; individual Lmo3 null mice show no discernible phenotype, indicating LMO3 is dispensable when LMO1 is present.\",\n      \"method\": \"Gene targeting (knockout mice), compound Lmo1/Lmo3 double null mutation, phenotypic analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic epistasis via double knockout in mouse, well-controlled developmental study\",\n      \"pmids\": [\"14966285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Lmo1, Lmo2, and Lmo3 are expressed in distinct but partially overlapping cell-type-specific patterns in the adult mouse brain including hippocampus, caudate-putamen, and cortex; seizure activity differentially regulates their expression—Lmo1 mRNA increases while Lmo2 and Lmo3 mRNAs decrease in hippocampal neurons after kainic acid-induced limbic seizures, with maximal change at 6 h and return to baseline by 24 h.\",\n      \"method\": \"In situ hybridization, immunohistochemistry in transgenic reporter mice, kainic acid seizure model\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization by ISH/IHC with activity-regulated expression as functional correlate, single lab\",\n      \"pmids\": [\"9204936\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"LMO3 is a nuclear LIM-only scaffold protein that modulates transcription by forming protein complexes with partners including HEN2, HES1, and p53: in neuroblastoma it drives oncogenesis by assembling an LMO3/HEN2 complex that displaces the repressor HES1 from the Mash1 promoter, while also co-repressing p53 transcriptional activity without blocking its DNA binding; in lung adenocarcinoma LMO3 is a direct NKX2-1/FOXA1 transcriptional target required for cancer cell survival; in human adipocytes it is glucocorticoid-induced via GR/11β-HSD1 feedback and promotes PPARγ-dependent adipogenesis; and in hepatocellular and gastric cancers it promotes invasion and survival by interacting with LATS1 to suppress Hippo/YAP signaling and by activating Akt/mTOR/GSK3β pathways, respectively.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"LMO3 is a nuclear LIM-only transcriptional scaffold that lacks intrinsic DNA-binding activity and instead modulates gene expression by assembling protein–protein complexes with diverse transcription factors and signaling kinases. In neuroblastoma, LMO3 forms a complex with the bHLH factor HEN2 that sequesters the repressor HES1 away from the Mash1 promoter, de-repressing Mash1 transcription and promoting tumor growth [PMID:15930276, PMID:21573214]; LMO3 also directly binds the p53 DNA-binding domain and co-represses p53-dependent transcription without blocking p53 chromatin occupancy [PMID:19995558]. Beyond neural cancers, LMO3 functions as a human-specific glucocorticoid-induced regulator of PPARγ-dependent adipogenesis [PMID:23823477], and in hepatocellular carcinoma it suppresses Hippo signaling by interacting with the kinase LATS1 to block YAP phosphorylation, thereby driving invasion and anoikis resistance [PMID:30219064]. Lmo3-null mice are viable due to functional redundancy with Lmo1, but compound Lmo1/Lmo3 double-null mice die perinatally, establishing an essential shared developmental role [PMID:14966285].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Establishing that LMO3 is expressed in specific neuronal populations in the adult brain and is dynamically regulated by neural activity resolved where this LIM-only gene operates in the CNS.\",\n      \"evidence\": \"In situ hybridization and immunohistochemistry in mouse brain with kainic acid seizure model\",\n      \"pmids\": [\"9204936\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Downstream transcriptional targets in neurons remain unidentified\",\n        \"Functional consequence of seizure-induced LMO3 downregulation is unknown\"\n      ]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstrating that Lmo3-null mice are phenotypically normal but Lmo1/Lmo3 double-null mice die perinatally established functional redundancy between LMO1 and LMO3 during development and revealed an essential collective role.\",\n      \"evidence\": \"Gene-targeted knockout mice; compound Lmo1/Lmo3 double-null phenotypic analysis\",\n      \"pmids\": [\"14966285\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Specific cell types or developmental processes requiring LMO1/LMO3 not identified\",\n        \"Whether LMO3 and LMO1 share the same protein partners in embryogenesis is unknown\"\n      ]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identifying LMO3 as a nuclear interactor of HEN2 that promotes neuroblastoma growth and tumorigenesis established LMO3 as an oncogene and defined its first binding partner.\",\n      \"evidence\": \"Co-immunoprecipitation, immunostaining, stable overexpression in SH-SY5Y cells, soft-agar assay, and nude-mouse xenograft\",\n      \"pmids\": [\"15930276\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Transcriptional targets downstream of the LMO3/HEN2 complex were not identified\",\n        \"The domain(s) of LMO3 required for HEN2 binding were not mapped\"\n      ]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showing that LMO3 directly binds the p53 DNA-binding domain and co-represses p53 target gene transcription — without blocking p53 chromatin occupancy — revealed a second transcription-factor partner and an unexpected co-repressor mechanism.\",\n      \"evidence\": \"In vitro binding, co-immunoprecipitation, ChIP, and luciferase reporter assays\",\n      \"pmids\": [\"19995558\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The co-repressor mechanism (e.g., recruited histone modifiers) is not defined\",\n        \"Whether p53 co-repression contributes to neuroblastoma oncogenesis in vivo is untested\"\n      ]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Elucidating that the LMO3/HEN2 complex displaces the repressor HES1 from the Mash1 promoter to de-repress Mash1 transcription provided the first complete mechanistic circuit for LMO3-driven neuroblastoma gene regulation.\",\n      \"evidence\": \"ChIP, luciferase reporter, co-immunoprecipitation, and siRNA knockdown in SH-SY5Y cells\",\n      \"pmids\": [\"21573214\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether Mash1 is the sole or primary oncogenic effector downstream of LMO3/HEN2 is unclear\",\n        \"Structural basis for HES1 displacement by the LMO3/HEN2 complex is unknown\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identifying LMO3 as a direct NKX2-1/FOXA1 transcriptional target required for survival in NKX2-1-amplified lung adenocarcinoma, and independently as a glucocorticoid-induced human-specific driver of PPARγ-dependent adipogenesis, broadened LMO3 function beyond neuroblastoma to distinct tissue contexts.\",\n      \"evidence\": \"ChIP-seq cistromics with RNAi survival assays in lung cancer lines; GR pathway analysis with gain/loss-of-function in human adipose stromal cells\",\n      \"pmids\": [\"23322301\", \"23823477\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct transcriptional targets of LMO3 in adipocytes and lung cancer cells are not defined\",\n        \"Protein partners mediating LMO3 action in adipogenesis are unknown\",\n        \"Why LMO3 adipogenic function is absent in mouse remains unexplained\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrating that miR-630 directly targets LMO3 mRNA in NSCLC and that miR-101 indirectly suppresses LMO3 via epigenetic remodeling of its promoter in glioma established upstream regulatory layers controlling LMO3 expression in cancers.\",\n      \"evidence\": \"Luciferase 3′-UTR reporter with rescue experiments (miR-630/NSCLC); MeDIP-Chip and ChIP for histone marks (miR-101/glioma)\",\n      \"pmids\": [\"26328011\", \"25829251\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Single-lab findings for each miRNA; independent replication lacking\",\n        \"Whether these miRNAs regulate LMO3 in non-cancer contexts is untested\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identifying LMO3 as a direct LATS1 interactor that suppresses Hippo/YAP signaling in HCC, and as an activator of Akt/mTOR/GSK3β signaling in gastric cancer, revealed that LMO3 scaffolding extends to cytoplasmic kinase pathways beyond classical transcriptional regulation.\",\n      \"evidence\": \"Co-immunoprecipitation of LMO3–LATS1, recombinant protein rescue, pharmacological inhibitors of mTOR and GSK3β in functional assays, in vivo metastasis model\",\n      \"pmids\": [\"30219064\", \"29436606\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"How a nuclear LIM-only protein accesses cytoplasmic LATS1 is mechanistically unexplained\",\n        \"Direct versus indirect activation of Akt by LMO3 is not resolved\",\n        \"Gastric cancer pathway findings are from a single lab without independent confirmation\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for LMO3 partner selectivity across tissues, the identity of direct transcriptional targets beyond Mash1, and whether the cytoplasmic kinase interactions (LATS1, Akt) require shuttling or are mediated by distinct LMO3 pools.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No crystal or cryo-EM structure of LMO3 in complex with any partner\",\n        \"Genome-wide direct target identification (e.g., CUT&RUN for LMO3-containing complexes) has not been performed\",\n        \"Nuclear–cytoplasmic distribution and shuttling of LMO3 have not been systematically characterized\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 2, 5]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 2, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1, 2]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0074160\", \"supporting_discovery_ids\": [1, 2, 3, 4]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 8]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 4, 5]}\n    ],\n    \"complexes\": [\n      \"LMO3/HEN2 transcriptional complex\"\n    ],\n    \"partners\": [\n      \"HEN2\",\n      \"HES1\",\n      \"TP53\",\n      \"LATS1\",\n      \"NKX2-1\",\n      \"FOXA1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}